Mizuho lowered the firm’s price target on Medtronic (MDT) to $98 from $100 and keeps an Outperform rating on the shares. The firm says the diabetes spinoff is designed to improve the company’s’ earnings growth profile. It believes Medtronic’s stock discount “still looks too steep considering multiple growth shots on goal potential” from the portfolio.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $92 from $94 at Baird
- Medtronic Reports Strong FY25 Results and Dividend Increase
- Medtronic’s Strong Financial Performance and Promising Growth Outlook Justify Buy Rating
- Medtronic’s Mixed Outlook: Hold Rating Amid Profitability Concerns and Strategic Initiatives
- Medtronic sees Q1 EPS $1.22-$1.24, consensus $1.32